The nuclear factor erythroid 2 (NFE2) antibody is a tool used to study the NFE2 transcription factor, a member of the CNC-bZIP family that includes NRF1. NRF2. and NRF3. NFE2 plays a critical role in regulating erythroid and megakaryocytic differentiation, particularly in hematopoiesis. It binds to antioxidant response elements (AREs) in DNA, influencing the expression of genes involved in heme biosynthesis, globin production, and platelet formation. Structurally, NFE2 consists of a p45 subunit, which heterodimerizes with small Maf proteins (e.g., MafG) to activate or repress target genes.
Research on NFE2 has highlighted its involvement in disorders such as myeloproliferative neoplasms (MPNs), where mutations or dysregulation may contribute to abnormal blood cell proliferation. Antibodies targeting NFE2 are essential for detecting its expression and localization in cells or tissues via techniques like Western blotting, immunohistochemistry, or ChIP-seq. These studies help elucidate its role in oxidative stress responses, erythroid maturation, and disease mechanisms.
Interest in NFE2 antibodies also stems from their potential diagnostic and therapeutic applications, particularly in understanding conditions like thrombocytopenia or cancers with disrupted erythropoiesis. However, NFE2's functional overlap with other NRF family members, such as NRF2 (a key regulator of antioxidant defenses), necessitates careful experimental validation to ensure specificity in antibody-based assays. Ongoing studies aim to clarify NFE2's distinct pathways and interactions, advancing its relevance in hematology and molecular biology.